BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 28391009)

  • 1. The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment.
    Rudin S; Marable M; Huang RS
    Genomics Proteomics Bioinformatics; 2017 Apr; 15(2):82-93. PubMed ID: 28391009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia.
    Zgheib NK; Akra-Ismail M; Aridi C; Mahfouz R; Abboud MR; Solh H; Muwakkit SA
    Pharmacogenet Genomics; 2014 Aug; 24(8):387-96. PubMed ID: 25007187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
    Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Combined Presence of Hepatitis C Virus and Polymorphisms in Different Genes With Toxicities of Methotrexate and 6-Mercaptopurine in Children With Acute Lymphoblastic Leukemia.
    Abdelaziz DH; Elhosseiny NM; Khaleel SA; Sabry NA; Attia AS; El-Sayed MH
    Pediatr Blood Cancer; 2016 Sep; 63(9):1539-45. PubMed ID: 27163515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
    Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
    Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of TPMT, ITPA, and NUDT15 Variants during Mercaptopurine Treatment of Swedish Pediatric Patients with Acute Lymphoblastic Leukemia.
    Wahlund M; Nilsson A; Kahlin AZ; Broliden K; Myrberg IH; Appell ML; Berggren A
    J Pediatr; 2020 Jan; 216():150-157.e1. PubMed ID: 31635813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment.
    Kotur N; Lazic J; Ristivojevic B; Stankovic B; Gasic V; Dokmanovic L; Krstovski N; Milosevic G; Janic D; Zukic B; Pavlovic S
    Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32344632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methotrexate pharmacogenetics in Uruguayan adults with hematological malignant diseases.
    Giletti A; Vital M; Lorenzo M; Cardozo P; Borelli G; Gabus R; Martínez L; Díaz L; Assar R; Rodriguez MN; Esperón P
    Eur J Pharm Sci; 2017 Nov; 109():480-485. PubMed ID: 28887233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of SLCO1B1 polymorphism on maintenance therapy for childhood leukemia.
    Suzuki R; Fukushima H; Noguchi E; Tsuchida M; Kiyokawa N; Koike K; Ma E; Takahashi H; Kobayashi C; Nakajima-Yamaguchi R; Sakai A; Saito M; Iwabuchi A; Kato K; Nakao T; Yoshimi A; Sumazaki R; Fukushima T
    Pediatr Int; 2015 Aug; 57(4):572-7. PubMed ID: 25939871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLCO1B1 Polymorphisms are Associated With Drug Intolerance in Childhood Leukemia Maintenance Therapy.
    Eldem İ; Yavuz D; Cumaoğullari Ö; İleri T; Ünal İnce E; Ertem M; Doğanay Erdoğan B; Bindak R; Özdağ H; Şatiroğlu-Tufan NL; Uysal LZ
    J Pediatr Hematol Oncol; 2018 Jul; 40(5):e289-e294. PubMed ID: 29683944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of
    Kodidela S; Dorababu P; Thakkar DN; Dubashi B; Sundaram R; Muralidharan N; Nidanapu RP; Aribandi A; Pradhan SC; Uppugunduri CRS
    Genes (Basel); 2020 May; 11(6):. PubMed ID: 32481505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.
    Lopez-Lopez E; Martin-Guerrero I; Ballesteros J; Piñan MA; Garcia-Miguel P; Navajas A; Garcia-Orad A
    Pediatr Blood Cancer; 2011 Oct; 57(4):612-9. PubMed ID: 21387541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatotoxicity During Maintenance Therapy and Prognosis in Children With Acute Lymphoblastic Leukemia.
    Ebbesen MS; Nygaard U; Rosthøj S; Sørensen D; Nersting J; Vettenranta K; Wesenberg F; Kristinsson J; Harila-Saari A; Schmiegelow K
    J Pediatr Hematol Oncol; 2017 Apr; 39(3):161-166. PubMed ID: 28060115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia.
    Dorababu P; Nagesh N; Linga VG; Gundeti S; Kutala VK; Reddanna P; Digumarti R
    Eur J Clin Pharmacol; 2012 Apr; 68(4):379-87. PubMed ID: 22009189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of NUDT15 on incidence of neutropenia in children with acute lymphoblastic leukemia.
    Buaboonnam J; Sripatanatadasakul P; Treesucon A; Glomglao W; Siraprapapat P; Narkbunnam N; Vathana N; Takpradit C; Phuakpet K; Pongtanakul B; Tongsai S; Sinlapamongkolkul P; Sanpakit K
    Pediatr Int; 2019 Aug; 61(8):754-758. PubMed ID: 31166660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia.
    Khera S; Trehan A; Bhatia P; Singh M; Bansal D; Varma N
    Cancer Chemother Pharmacol; 2019 Feb; 83(2):341-348. PubMed ID: 30474703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations.
    Toksvang LN; Lee SHR; Yang JJ; Schmiegelow K
    Leukemia; 2022 Jul; 36(7):1749-1758. PubMed ID: 35654820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of variants in folate metabolism genes on 6-mercaptopurine induced toxicity during treatment for childhood acute lymphocytic leukemia.
    Milosevic G; Kotur N; Lazic J; Krstovski N; Stankovic B; Zukic B; Janic D; Jurisic V; Pavlovic S; Dokmanovic L
    J BUON; 2019; 24(5):2075-2083. PubMed ID: 31786878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma.
    Shimasaki N; Mori T; Torii C; Sato R; Shimada H; Tanigawara Y; Kosaki K; Takahashi T
    J Pediatr Hematol Oncol; 2008 May; 30(5):347-52. PubMed ID: 18458567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mercaptopurine induced myelosuppression in a child with a
    Gupta N; Magatha LS; Jayaraman D; Scott JX; Antony SB; Koshy T
    J Oncol Pharm Pract; 2023 Jun; 29(4):999-1001. PubMed ID: 36341754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.